AX-2025-018819 · L-Carnosine · FGP lot FGP-2501-G8414

Section 1

Results

Measured against the index acceptance specification for the short bioregulator peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	99.56	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.44	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — free histidine (−71 Da)	0.16	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	226.1066	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	226.1064	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-0.7	ppm	± 20	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	8.59	%	≤ 12.0	PASS
Counter-ion	no ionisable counter-ion expected	N/A	—	not applicable	NOT TESTED
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.49	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	7.66	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	3.49	min	3.49 ± 0.20 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.15	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	56,096	—	≥ 20,000	PASS
Resolution to nearest impurity	vs D-carnosine epimer	0.93	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 56,096, and skew follows the reported asymmetry factor of 1.15. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.16 % impurity against a 99.56 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	L-Carnosine — main peak	3.49	4,838,925	99.56	—
2	free histidine (−71 Da)	3.34	7,776	0.16	-71.037
3	anserine (methylcarnosine, +14 Da)	3.60	6,804	0.14	+14.016
4	D-carnosine epimer	3.43	3,402	0.07	0.000
5	β-alanine (−137 Da)	3.28	3,402	0.07	-137.059
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 226.1066 Da, computed from C9H14N4O3. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 226.1064 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
1+	227.1139	227.1137	-0.0002	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.56	divergence +0.15 pp vs batch median
Total impurities (% area)	0.10	0.44
Largest single impurity (% area)	not stated	0.16
Water (%)	7.4	8.59
Counter-ion (%)	not stated	N/A
Peptide content (%w/w)	87.8	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 13 d) → laboratory (courier, cold pack, 9 d) → assay.
Assay date: 20 Mar 2025
Submitted to the index: 31 Mar 2025
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: METHOD LIMITED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

peak_integrator31 Mar 2025

99.56 % on L-Carnosine sits at the top of what this index sees. Read it with the method: PeptideMeter ran a 28 min gradient here, and the compound fingerprint names a mass-identical species that a shorter run folds into the main peak. On this gradient the figure is well founded.

scale_up_delta31 Mar 2025

Purity usually falls between gram and kilogram scale. A figure of 99.56 % on a commercial lot rather than a laboratory batch is the more informative version of this result.

quarter_over_quarter31 Mar 2025

Single records do not establish trends. Where this supplier's quarterly medians are stable across four quarters, a result like this reads as the process rather than the draw — and the timeline page is where to check that.

Section 7

Related records

Same batch — lot FGP-2501-G8414 n=4

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-018816	FGP-2501-G8414	Janoshik	2025-Q1	99.72	8.21	91.5	Buyer-sourced	1	MARGINAL
AX-2025-018817	FGP-2501-G8414	Medutest	2025-Q1	99.78	8.56	—	Laboratory-retained	0	PASS
AX-2025-018818	FGP-2501-G8414	Janoshik	2025-Q1	99.93	8.48	101.0	Supplier-supplied	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent L-Carnosine records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043257	CPC	CPC-2603-G9615	VendorInvestigate	2026-Q3	98.20	10.41	102.2	Buyer-sourced	0	FAIL
AX-2026-043256	CPC	CPC-2603-G9615	Janoshik	2026-Q3	99.02	10.17	104.1	Supplier-supplied	0	PASS
AX-2026-043258	CPC	CPC-2603-G9615	Medutest	2026-Q3	98.95	10.15	97.8	Buyer-sourced	0	FAIL
AX-2026-043189	GL Biochem	GLBI-2512-S8068	Medutest	2026-Q2	99.60	8.49	—	Buyer-sourced	0	PASS
AX-2026-043190	GL Biochem	GLBI-2512-S8068	Janoshik	2026-Q2	99.46	8.66	—	Buyer-sourced	0	PASS
AX-2026-043194	GL Biochem	GLBI-2512-S8068	Janoshik	2026-Q2	99.62	8.16	90.4	Buyer-sourced	0	PASS
AX-2026-043195	GL Biochem	GLBI-2512-S8068	Janoshik	2026-Q2	99.16	8.69	89.4	Laboratory-retained	1	MARGINAL
AX-2026-043188	GL Biochem	GLBI-2512-S8068	PeptideMeter	2026-Q2	99.62	8.43	—	Buyer-sourced	0	PASS

Other recent FGP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-041643	Semaglutide	FGP-2602-M8547	Janoshik	2026-Q3	99.31	2.79	100.7	Buyer-sourced	PASS
AX-2026-041638	Semaglutide	FGP-2602-M8547	Janoshik	2026-Q3	99.40	2.75	105.8	Buyer-sourced	PASS
AX-2026-041641	Semaglutide	FGP-2602-M8547	PeptideMeter	2026-Q3	98.98	2.38	105.0	Buyer-sourced	PASS
AX-2026-041610	Tirzepatide	FGP-2603-L7753	Janoshik	2026-Q3	98.81	2.45	101.0	Buyer-sourced	PASS
AX-2026-041637	Semaglutide	FGP-2602-M8547	PeptideMeter	2026-Q3	99.40	2.83	—	Laboratory-retained	PASS
AX-2026-041642	Semaglutide	FGP-2602-M8547	PeptideMeter	2026-Q3	98.78	2.24	—	Buyer-sourced	PASS
AX-2026-041609	Tirzepatide	FGP-2603-L7753	Janoshik	2026-Q3	98.52	2.00	98.0	Buyer-sourced	PASS
AX-2026-041636	Semaglutide	FGP-2602-M8547	Nordanalyt	2026-Q3	99.39	2.17	—	Buyer-sourced	PASS